遺伝子治療市場- 世界の産業規模、シェア、動向、機会、および予測、2018年～2028年ベクタータイプ別、送達方法別、適応症別、地域別、競合

遺伝子治療の世界市場は、2022年に60億1,000万米ドルと評価され、予測期間中に大幅な成長が見込まれており、予想年間平均成長率（CAGR）は9.26%で、2028年には101億3,000万米ドルに達すると予測されています。

遺伝子治療は、病気の原因となる遺伝子の組み合わせの欠損や欠陥を修正、置換、補完することによって病気を治療するものです。遺伝子治療は、変性疾患と闘う上で非常に望ましい研究フロンティアとして浮上しています。

主要市場促進要因

• 1.遺伝子研究の進歩：疾患の遺伝的基盤に関する洞察が深まり、科学者たちは様々な疾患の原因となる特定の遺伝子を特定できるようになっています。この知識は、欠陥のある遺伝子を修正または置換し、疾患の根本原因に取り組むことができる正確な遺伝子治療を開発する上で極めて重要です。CRISPR-Cas9、TALEN、ジンクフィンガーヌクレアーゼなどの遺伝子編集技術の進歩は、正確で効率的な遺伝子改変を可能にすることで、遺伝子治療に革命をもたらしました。その結果、遺伝子疾患の治療に新たな道が開かれました。
• 2.遺伝性疾患の有病率の上昇：遺伝性疾患と診断される患者数の増加は、有効な治療法に対するアンメット・メディカル・ニーズを浮き彫りにしています。遺伝子治療は、遺伝的な原因ではなく対症療法で対処されることの多いこれらの疾患に対して、的を絞った長期的な解決策を提供します。遺伝性疾患の有病率の増加は潜在的な患者層を拡大し、遺伝子治療の需要と市場機会を促進します。
• 3.共同研究とパートナーシップ：遺伝子治療には、分子生物学、遺伝学、バイオテクノロジー、臨床研究、薬事など、学際的なアプローチが必要です。共同研究により、多様な分野の知識、専門知識、ベストプラクティスが共有され、イノベーションが促進され、より高度な遺伝子治療の開発が促進されます。パートナーシップは専門的な技術やツールへのアクセスを可能にし、遺伝子治療開発におけるブレークスルーを促進します。また、スケーラブルな製造技術の開発を支援し、複雑な規制状況を乗り切るためのサポートを提供することで、最終的に市場の成長に寄与しています。

主な市場課題

• 1.技術的複雑性：効果的な遺伝子治療の開発には、遺伝学、分子生物学、複雑な細胞プロセスに対する深い理解が必要です。特定の遺伝子を正確に標的とし、改変する治療法の設計は複雑であるため、研究開発期間が長期化する可能性があります。正確かつ制御された遺伝子導入を達成するための課題は、潜在的な予期せぬ結果とともに技術的困難をもたらし、治療の成功に影響を及ぼします。
• 2.高い開発コスト：遺伝子治療の開発には、多大な初期研究、大規模な臨床試験費用、規制遵守のための費用、熟練したチームの構築が必要です。最先端技術や高度な実験機器も、高い開発コストの一因となっています。また、遺伝子治療分野は専門性が高いため、専門家の確保にもコストがかかります。

主な市場動向

• 1.治療ターゲットの拡大：新たな治療標的の同定により、遺伝子治療の応用範囲は、がん、心血管疾患、神経変性疾患、希少疾患のような複雑な疾患にまで広がっています。このような多様化は、より多くの患者を惹きつけ、商業的機会を増やすことで市場の成長を促進します。また、イノベーションを促進し、研究を加速させ、より多様な臨床試験の状況をもたらします。
• 2.CRISPRベースの治療法の成長：遺伝子編集におけるCRISPR-Cas9技術の精度は、遺伝子治療研究を加速させています。CRISPR-Cas9は遺伝子を正確に編集することができるため、治療の有効性と安全性が高まる。CRISPRベースの治療法は、単発性疾患から複雑な疾患まで幅広い遺伝性疾患に対応できる可能性があり、規制当局の承認プロセスも簡素化されます。CRISPR技術の利用しやすさは世界の共同研究に拍車をかけ、競争、革新、市場拡大をもたらしています。

セグメント別の洞察

ベクタータイプの洞察：非ウイルス性ベクターセグメントは、予測期間を通じて大きな市場成長が見込まれます。非ウイルス性ベクターは、ウイルス性ベクターと比較して免疫反応のリスクが低減され、より安全なプロファイルを提供します。宿主ゲノムに組み込まれるリスクが低いため、長期的な治療応用が可能になります。また、非ウイルス性ベクターは製造工程を簡素化し、製造コストの削減や拡張性を可能にする可能性があります。その安全性の優位性は、規制当局の経路をスムーズにし、承認を迅速化することにつながります。非ウイルス性ベクター技術の出現は、多様な業界プレイヤーを惹きつけ、競争、革新、市場拡大を促進します。

送達方法の洞察生体内投与は、非侵襲的であるため患者に受け入れられやすく、外科的処置に伴うリスクが軽減されることから、市場を独占しています。In vivo遺伝子治療は全身投与が可能であるため、より広範な患者が利用でき、複数の臓器や組織に影響を及ぼす疾患にも適しています。その全身的効果は遺伝子異常が広範囲に及ぶ疾患にとって有益であり、長期にわたる効果が期待できます。In vivo遺伝子治療の多用途性は、多様な研究者、開発者、企業を遺伝子治療市場に惹きつけています。

地域別洞察

北米、特に米国は2022年の遺伝子治療市場をリードしてきました。これは、同地域の強固な研究とイノベーションのエコシステムが、遺伝子治療の研究と臨床試験にさまざまなところから多額の投資を引き寄せているためです。北米は、確立された臨床試験インフラ、遺伝子治療に特化した多数のバイオテクノロジー企業、高度なヘルスケアインフラを誇り、遺伝子治療の研究、臨床応用、採用に有利な環境を作り出しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 臨床試験分析

第5章 顧客の声

第6章 遺伝子治療の世界市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • ベクタータイプ別（ウイルスベクター、非ウイルスベクター）
  • 送達方法別（生体内、生体外）
  • 適応症別（希少疾患、がん、神経疾患、その他）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2022年）
• 市場マップ
  • ベクタータイプ別
  • 送達方法別
  • 適応症別
  • 地域別

第7章 北米遺伝子治療市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • ベクタータイプ別
  • デリバリー方法別
  • 適応症別
  • 国別
• 北米国別分析
  • 米国
  • カナダ
  • メキシコ

第8章 欧州遺伝子治療市場の展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • ベクタータイプ別
  • 送達方法別
  • 適応症別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第9章 アジア太平洋地域の遺伝子治療市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • ベクタータイプ別
  • デリバリー方法別
  • 適応症別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第10章 南米遺伝子治療市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • ベクタータイプ別
  • 送達方法別
  • 適応症別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカの遺伝子治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • ベクタータイプ別
  • 送達方法別
  • 適応症別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品上市

第14章 遺伝子治療の世界市場：SWOT分析

第15章 遺伝子治療の世界市場：SWOT分析資金調達分析

第16章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第17章 競合情勢

• Business Overview
• Product Offerings
• Recent Developments
• Financials（As Reported）
• Key Personnel
• SWOT Analysis
  • REGENXBIO Inc.
  • Oxford Biomedica PLC.
  • Voyager Therapeutics Inc.
  • Human Stem Cells Institute
  • Dimension Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi-Aventis
  • Applied genetic technologies corporation.
  • F. Hoffmann-la Roche ltd.
  • Bluebird bio, Inc.
  • Novartis AG
  • Uniqure N.V.

第18章 戦略的提言

The Global Gene Therapy Market, valued at USD 6.01 Billion in 2022, is poised for substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 9.26% and is expected to reach USD 10.13 Billion by 2028. Gene therapy involves the treatment of illnesses by modifying, replacing, or supplementing missing or defective genetic combinations responsible for the disease. It has emerged as a highly desirable research frontier in combating degenerative diseases.

The increasing prevalence of cancer and other chronic diseases worldwide is driving the need for gene therapy. Anticipated advancements in gene therapies, expected to receive approvals in the coming years, are set to contribute significantly to the growth of the gene therapy market during the forecast period. Gene therapies are designed to address diseases by altering genetic information, such as deactivating malfunctioning genes or substituting a disease-causing gene with a healthy one. This approach has demonstrated effectiveness in treating a variety of disorders, including diabetes, cancer, heart disease, and AIDS.

Key Market Drivers

• 1. Advancements in Genetic Research: Growing insights into the genetic basis of diseases have empowered scientists to pinpoint specific genes responsible for various disorders. This knowledge is pivotal in developing precise gene therapies that can rectify or replace defective genes, tackling the root causes of diseases. Advancements in gene editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, have revolutionized gene therapy by enabling accurate and efficient gene modifications. This, in turn, has opened new avenues for treating genetic disorders.

• 2. Rising Prevalence of Genetic Disorders: The increasing number of individuals diagnosed with genetic disorders underscores the unmet medical need for effective treatments. Gene therapy offers targeted and long-lasting solutions for these disorders, which are often managed symptomatically rather than at their genetic source. The growing prevalence of genetic disorders expands the potential patient base, driving demand for gene therapy and market opportunities.

• 3. Collaborations and Partnerships: Gene therapy necessitates a multidisciplinary approach, involving molecular biology, genetics, biotechnology, clinical research, and regulatory affairs. Collaborations facilitate the pooling of knowledge, expertise, and best practices across diverse fields, fostering innovation and expediting the development of more advanced gene therapies. Partnerships grant access to specialized technologies and tools, promoting breakthroughs in gene therapy development. They also aid in the development of scalable manufacturing techniques and provide support in navigating complex regulatory landscapes, ultimately contributing to market growth.

Key Market Challenges

• 1. Technical Complexity: The development of effective gene therapies requires a profound understanding of genetics, molecular biology, and intricate cellular processes. The complexity of designing therapies that accurately target and modify specific genes can lead to prolonged research and development timelines. Challenges in achieving precise and controlled gene delivery, along with potential unintended consequences, pose technical difficulties, affecting therapy success.

• 2. High Development Costs: Gene therapy development involves significant initial research, extensive clinical trial costs, regulatory compliance expenses, and the need to build skilled teams. Cutting-edge technologies and sophisticated laboratory equipment also contribute to high development costs. Attracting and retaining experts in the field can be expensive due to its specialized nature.

Key Market Trends

• 1. Expanding Therapeutic Targets: The identification of new therapeutic targets broadens the scope of gene therapy applications to include complex diseases like cancer, cardiovascular diseases, neurodegenerative disorders, and rare conditions. This diversification attracts a larger patient base, driving market growth by increasing commercial opportunities. It fosters innovation, accelerates research, and results in a more diverse clinical trial landscape.

• 2. Growing CRISPR-Based Therapies: CRISPR-Cas9 technology's precision in gene editing has accelerated gene therapy research. Its ability to target and modify genes accurately enhances therapy efficacy and safety. CRISPR-based therapies have the potential to address a wide range of genetic disorders, from monogenic to complex conditions, and simplify the regulatory approval process. The accessibility of CRISPR technology has spurred global collaboration, leading to competition, innovation, and market expansion.

Segmental Insights

Vector Type Insights: The Non-Viral Vector segment is expected to witness significant market growth throughout the forecast period. Non-viral vectors offer a safer profile with reduced immune response risks compared to viral vectors. Their lower risk of integrating into the host genome enhances long-term therapeutic applications. Non-viral vectors also simplify manufacturing processes, potentially reducing production costs and enabling scalability. Their safety advantages can lead to smoother regulatory pathways, expediting approvals. The emergence of non-viral vector technologies attracts a diverse range of industry players, promoting competition, innovation, and market expansion.

Delivery Method Insights: The In-Vivo segment has dominated the market due to its non-invasive nature, making it more acceptable to patients and reducing risks associated with surgical procedures. In vivo gene therapy can be administered systemically, making it accessible to a broader range of patients and suitable for conditions affecting multiple organs or tissues. Its systemic effect can be beneficial for diseases with widespread genetic abnormalities, offering long-lasting effects. In vivo gene therapy's versatility attracts a diverse range of researchers, developers, and companies to the gene therapy market.

Regional Insights

North America, specifically the United States, has been the leader in the gene therapy market in 2022. This is attributed to the region's robust research and innovation ecosystem, attracting significant investments from various sources into gene therapy research and clinical trials. North America boasts well-established clinical trial infrastructure, a multitude of biotechnology companies dedicated to gene therapy, and advanced healthcare infrastructure, creating a favorable environment for gene therapy research, clinical application, and adoption.

Key Market Players

• REGENXBIO Inc.
• Oxford Biomedica PLC.
• Voyager Therapeutics Inc.
• Human Stem Cells Institute
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Sanofi-Aventis
• Applied genetic technologies corporation.
• F. Hoffmann-la roche ltd.
• Bluebird bio, inc.
• Novartis ag
• Uniqure n.v

Report Scope:

In this report, the Global Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Gene Therapy Market, By Vector Type:

• Viral Vector
• Non-Viral Vector

Gene Therapy Market, By Delivery Method:

• In-Vivo
• Ex-Vivo

Gene Therapy Market, By Indication:

• Rare Diseases
• Cancer
• Neurological Diseases
• Others

Gene Therapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Gene Therapy Market.

Available Customizations:

• Global Gene Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

• 4.1 Ongoing Clinical Trials
• 4.2 Completed Clinical Trials
• 4.3 Terminated Clinical Trials
• 4.4 Breakdown of Pipeline, By Development Phase
• 4.5 Breakdown of Pipeline, By Status
• 4.6 Breakdown of Pipeline, By Study Type
• 4.7 Breakdown of Pipeline, By Region
• 4.8 Clinical Trials Heat Map

5. Voice of Customer

6. Global Gene Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 5.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
    • 5.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
  • 6.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 6.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 6.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 6.2.5. By Company (2022)
• 6.3. Market Map
  • 5.3.1 By Vector Type
  • 5.3.2 By Delivery Method
  • 5.3.3 By Indication
  • 5.3.4 By Region

7. North America Gene Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 7.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
    • 7.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
  • 7.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 7.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Gene Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vector Type
      • 7.3.1.2.2. By Delivery Method
      • 7.3.1.2.3. By Indication
  • 7.3.2. Canada Gene Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vector Type
      • 7.3.2.2.2. By Delivery Method
      • 7.3.2.2.3. By Indication
  • 7.3.3. Mexico Gene Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vector Type
      • 7.3.3.2.2. By Delivery Method
      • 7.3.3.2.3. By Indication

8. Europe Gene Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 8.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
    • 8.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
  • 8.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 8.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Gene Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vector Type
      • 8.3.1.2.2. By Delivery Method
      • 8.3.1.2.3. By Indication
  • 8.3.2. Germany Gene Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vector Type
      • 8.3.2.2.2. By Delivery Method
      • 8.3.2.2.3. By Indication
  • 8.3.3. United Kingdom Gene Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vector Type
      • 8.3.3.2.2. By Delivery Method
      • 8.3.3.2.3. By Indication
  • 8.3.4. Italy Gene Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vector Type
      • 8.3.4.2.2. By Delivery Method
      • 8.3.4.2.3. By Indication
  • 8.3.5. Spain Gene Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vector Type
      • 8.3.5.2.2. By Delivery Method
      • 8.3.5.2.3. By Indication

9. Asia-Pacific Gene Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 9.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
    • 9.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
  • 9.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 9.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 9.2.4. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Gene Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vector Type
      • 9.3.1.2.2. By Delivery Method
      • 9.3.1.2.3. By Indication
  • 9.3.2. India Gene Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vector Type
      • 9.3.2.2.2. By Delivery Method
      • 9.3.2.2.3. By Indication
  • 9.3.3. Japan Gene Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vector Type
      • 9.3.3.2.2. By Delivery Method
      • 9.3.3.2.3. By Indication
  • 9.3.4. South Korea Gene Therapy Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Vector Type
      • 9.3.4.2.2. By Delivery Method
      • 9.3.4.2.3. By Indication
  • 9.3.5. Australia Gene Therapy Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Vector Type
      • 9.3.5.2.2. By Delivery Method
      • 9.3.5.2.3. By Indication

10. South America Gene Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 10.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
    • 10.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
  • 10.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 10.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gene Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vector Type
      • 10.3.1.2.2. By Delivery Method
      • 10.3.1.2.3. By Indication
  • 10.3.2. Argentina Gene Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vector Type
      • 10.3.2.2.2. By Delivery Method
      • 10.3.2.2.3. By Indication
  • 10.3.3. Colombia Gene Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vector Type
      • 10.3.3.2.2. By Delivery Method
      • 10.3.3.2.3. By Indication

11. Middle East and Africa Gene Therapy Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
    • 11.2.1.1 By Viral Vectors (Retro Viral Vectors, Adeno-associated Viral Vectors, Others)
    • 11.2.1.2 By Non-Viral Vectors (Oligonucleotides, Others)
  • 11.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 11.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Gene Therapy Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Vector Type
      • 11.3.1.2.2. By Delivery Method
      • 11.3.1.2.3. By Indication
  • 11.3.2. Saudi Arabia Gene Therapy Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Vector Type
      • 11.3.2.2.2. By Delivery Method
      • 11.3.2.2.3. By Indication
  • 11.3.3. UAE Gene Therapy Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Vector Type
      • 11.3.3.2.2. By Delivery Method
      • 11.3.3.2.3. By Indication

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Development
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Global Gene Therapy Market: SWOT Analysis

15. Funding Analysis

16. Porter's Five Forces Analysis

• 16.1. Competition in the Industry
• 16.2. Potential of New Entrants
• 16.3. Power of Suppliers
• 16.4. Power of Customers
• 16.5. Threat of Substitute Products

17. Competitive Landscape

• 17.1. Business Overview
• 17.2. Product Offerings
• 17.3. Recent Developments
• 17.4. Financials (As Reported)
• 17.5. Key Personnel
• 17.6. SWOT Analysis
  • 15.6.1 REGENXBIO Inc.
  • 15.6.2 Oxford Biomedica PLC.
  • 15.6.3 Voyager Therapeutics Inc.
  • 15.6.4 Human Stem Cells Institute
  • 15.6.5 Dimension Therapeutics, Inc.
  • 15.6.6 Bristol-Myers Squibb Company
  • 15.6.7 Sanofi-Aventis
  • 15.6.8 Applied genetic technologies corporation.
  • 15.6.9 F. Hoffmann-la Roche ltd.
  • 15.6.10 Bluebird bio, Inc.
  • 15.6.11 Novartis AG
  • 15.6.12 Uniqure N.V.

18. Strategic Recommendations